Cofoe Medical Technology Co.Ltd.
Cofoe Medical Technology Co.,Ltd. manufactures and sells professional household medical devices in China. It offers blood pressure monitors, nebulizers, thermometers, fingertip pulse oximeters, oxygen concentrators, fetal doppler, and CPAP and BPAP devices; in vitro diagnostic products, including glucose meters, HCG test kits, H.Pylori, UTM, DNA/RNA extraction reagents, and respiratory tract infe… Read more
Cofoe Medical Technology Co.Ltd. (301087) - Net Assets
Latest net assets as of June 2025: CN¥4.77 Billion CNY
Based on the latest financial reports, Cofoe Medical Technology Co.Ltd. (301087) has net assets worth CN¥4.77 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.35 Billion) and total liabilities (CN¥1.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.77 Billion |
| % of Total Assets | 75.21% |
| Annual Growth Rate | 51.59% |
| 5-Year Change | 382.57% |
| 10-Year Change | N/A |
| Growth Volatility | 155.49 |
Cofoe Medical Technology Co.Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Cofoe Medical Technology Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cofoe Medical Technology Co.Ltd. (2019–2024)
The table below shows the annual net assets of Cofoe Medical Technology Co.Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.80 Billion | -2.16% |
| 2023-12-31 | CN¥4.91 Billion | -2.48% |
| 2022-12-31 | CN¥5.03 Billion | +1.36% |
| 2021-12-31 | CN¥4.97 Billion | +398.93% |
| 2020-12-31 | CN¥995.17 Million | +66.02% |
| 2019-12-31 | CN¥599.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cofoe Medical Technology Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1629.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥764.13 Million | 15.93% |
| Other Components | CN¥4.03 Billion | 84.07% |
| Total Equity | CN¥4.80 Billion | 100.00% |
Cofoe Medical Technology Co.Ltd. Competitors by Market Cap
The table below lists competitors of Cofoe Medical Technology Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VALNEVA SE SP.ADS/2
F:AYJ0
|
$667.13 Million |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
$667.23 Million |
|
Transcat Inc
NASDAQ:TRNS
|
$667.36 Million |
|
DINE S.A.B. de C.V
MX:DINEB
|
$667.42 Million |
|
Motorcomm Electronic Technology Co. Ltd. A
SHG:688515
|
$666.84 Million |
|
Kissei Pharmaceutical Co. Ltd
PINK:KSPHF
|
$666.75 Million |
|
ORIC PHARMAC.INC.DL-0001
F:4TZ
|
$666.70 Million |
|
HEROUX-DEV.
F:5D6
|
$666.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cofoe Medical Technology Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,899,195,275 to 4,796,596,352, a change of -102,598,922 (-2.1%).
- Net income of 311,750,944 contributed positively to equity growth.
- Dividend payments of 374,485,753 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥311.75 Million | +6.5% |
| Dividends Paid | CN¥374.49 Million | -7.81% |
| Other Changes | CN¥-39.86 Million | -0.83% |
| Total Change | CN¥- | -2.09% |
Book Value vs Market Value Analysis
This analysis compares Cofoe Medical Technology Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.39x to 2.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.82 | CN¥58.86 | x |
| 2020-12-31 | CN¥6.36 | CN¥58.86 | x |
| 2021-12-31 | CN¥23.78 | CN¥58.86 | x |
| 2022-12-31 | CN¥24.08 | CN¥58.86 | x |
| 2023-12-31 | CN¥23.41 | CN¥58.86 | x |
| 2024-12-31 | CN¥22.94 | CN¥58.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cofoe Medical Technology Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.50%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.45%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.34x
- Recent ROE (6.50%) is below the historical average (14.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 20.74% | 8.46% | 1.39x | 1.76x | CN¥64.04 Million |
| 2020 | 42.75% | 17.85% | 1.27x | 1.88x | CN¥324.79 Million |
| 2021 | 8.67% | 18.85% | 0.39x | 1.17x | CN¥-65.86 Million |
| 2022 | 6.01% | 10.13% | 0.46x | 1.28x | CN¥-200.35 Million |
| 2023 | 5.19% | 8.91% | 0.46x | 1.27x | CN¥-235.64 Million |
| 2024 | 6.50% | 10.45% | 0.46x | 1.34x | CN¥-167.91 Million |
Industry Comparison
This section compares Cofoe Medical Technology Co.Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cofoe Medical Technology Co.Ltd. (301087) | CN¥4.77 Billion | 20.74% | 0.33x | $666.89 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |